Behavioral health company LifeStance Health (NASDAQ: LFST) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 21.2% year on year to $403.5 million. On top of that, next quarter’s revenue guidance ($415 million at the midpoint) was surprisingly good and 3.9% above what analysts were expecting. Its GAAP profit of $0.04 per share was significantly above analysts’ consensus estimates.

Is now the time to buy LifeStance Health Group? Find out by accessing our full research report, it’s free.

“We delivered an exceptional quarter to begin the year, highlighted by strong revenue growth of 21%, net income growth of $13.5 million, and Adjusted EBITDA growth of 48%,” said Dave Bourdon, CEO of LifeStance.

Company Overview

With over 6,600 licensed mental health professionals treating more than 880,000 patients annually, LifeStance Health (NASDAQ: LFST) provides outpatient mental health services through a network of clinicians offering psychiatric evaluations, psychological testing, and therapy across 33 states.

Revenue Growth

Reviewing a company’s long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Thankfully, LifeStance Health Group’s 27.3% annualized revenue growth over the last five years was exceptional. Its growth beat the average healthcare company and shows its offerings resonate with customers.

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. LifeStance Health Group’s annualized revenue growth of 16.4% over the last two years is below its five-year trend, but we still think the results suggest healthy demand.

We can dig further into the company’s revenue dynamics by analyzing its number of clinicians, which reached 8,349 in the latest quarter. Over the last two years, LifeStance Health Group’s clinicians averaged 10.2% year-on-year growth. Because this number is lower than its revenue growth, we can see the company benefited from price increases.

This quarter, LifeStance Health Group reported robust year-on-year revenue growth of 21.2%, and its $403.5 million of revenue topped Wall Street estimates by 4.2%. Company management is currently guiding for a 20.2% year-on-year increase in sales next quarter.

Looking further ahead, sell-side analysts expect revenue to grow 13% over the next 12 months, a deceleration versus the last two years. Despite the slowdown, this projection is healthy and implies the market sees success for its products and services.

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.

Adjusted Operating Margin

Adjusted operating margin is a key measure of profitability. Think of it as net income (the bottom line) excluding the impact of non-recurring expenses, taxes, and interest on debt - metrics less connected to business fundamentals.

LifeStance Health Group was profitable over the last five years but held back by its large cost base. Its average adjusted operating margin of 2.7% was weak for a healthcare business.

On the plus side, LifeStance Health Group’s adjusted operating margin rose by 8.7 percentage points over the last five years, as its sales growth gave it operating leverage. The company’s two-year trajectory shows its performance was mostly driven by its recent improvements.

In Q1, LifeStance Health Group generated an adjusted operating margin profit margin of 9.3%, up 3 percentage points year on year. This increase was a welcome development and shows it was more efficient.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

LifeStance Health Group’s full-year EPS flipped from negative to positive over the last five years. This is encouraging and shows it’s at a critical moment in its life.

In Q1, LifeStance Health Group reported EPS of $0.04, up from $0 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects LifeStance Health Group’s full-year EPS of $0.06 to grow 63%.

Key Takeaways from LifeStance Health Group’s Q1 Results

We were impressed by LifeStance Health Group’s optimistic EBITDA guidance for next quarter, which blew past analysts’ expectations. We were also glad its EPS outperformed Wall Street’s estimates. Zooming out, we think this was a good print with some key areas of upside. The stock traded up 4.4% to $7.69 immediately after reporting.

LifeStance Health Group may have had a good quarter, but does that mean you should invest right now? We think that the latest quarter is only one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).